论文部分内容阅读
目的探讨CD155(poliovirus receptor,PVR)在结肠癌组织中的表达及与其临床病理特征的关系。方法应用组织微阵列技术和免疫组化Envision二步法,检测72例结肠癌组织及72例结肠正常组织中CD155的表达情况。结果CD155在正常对照组无阳性表达,结肠癌组阳性表达率为41.18%,两组阳性表达率比较有显著性差异(P<0.005);不同分化程度、不同Dukes分期之间CD155的阳性表达率差异无显著性(P>0.995,P>0.750),CD155阳性表达强度与分化程度及Dukes分期无相关关系(P=0.665,P=0.768)。结论CD155在结肠癌发生的早期就已出现,并存在于结肠癌的整个发展进程,可以利用CD155与NK细胞激活性受体(CD226/CD96)的结合,进一步激活NK细胞对结肠癌的活化杀伤性作用,从而为结肠癌的免疫治疗提供新的思路。
Objective To investigate the expression of CD155 (poliovirus receptor) in colon cancer and its relationship with clinicopathological features. Methods Tissue microarray technique and immunohistochemistry Envision two-step method were used to detect the expression of CD155 in 72 cases of colon cancer and 72 cases of normal colon tissues. Results There was no positive expression of CD155 in normal control group. The positive expression rate of CD155 in colon cancer group was 41.18%. The positive expression rate of CD155 in the two groups was significantly different (P <0.005). The positive rate of CD155 in different differentiation degree and Dukes stage There was no significant difference between the two groups (P> 0.995, P> 0.750). The positive expression of CD155 had no correlation with the degree of differentiation and Dukes stage (P = 0.665, P = 0.768). Conclusions CD155 has appeared in the early stage of colon cancer and exists in the whole development of colon cancer. CD155 can bind to NK cell activating receptor (CD226 / CD96) to further activate NK cells’ cytotoxicity towards colon cancer Role, so as to provide a new idea for the immunotherapy of colon cancer.